Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Immunology | Musculoskeletal | Rheumatology | Nephrology
Disease Category: Systemic Lupus Erythematosus
Location: United States, NY

Clinical Trial Details

Overview

Research Study Summary

Systemic Lupus Erythematosus (SLE) - Adults

Purpose

People with systemic lupus erythematosus are asked to participate in a research study being conducted by The Feinstein Institute for Medical Research.

Patient Inclusion Criteria
You may be eligible to participate in this study if you:

  • Are at least 18 years of age or older
  • Have been diagnosed with SLE
  • Have active lupus nephritis

Patient Exclusion Criteria
You may not participate in this study if you:

  • Have currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia.
  • Have severe renal impairment
  • Have a history of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin
  • Have severe chronic pulmonary disease
  • Have significant or uncontrolled concomitant diseases in any organ system not related to SLE (e.g. renal thrombosis, atherosclerotic cardiovascular disease, diabetes mellitus, accelerated hypertension, poorly controlled COPD or asthma
  • Have a concomitant condition (e.g. asthma, Crohn's disease, etc), which has required treatment with systemic corticosteroid (excluding topical or inhaled) at any time in the 52 weeks prior to screening.
  • Have HIV or chronic active Hepatitis B or chronic active Hepatitis C infection
  • Have a known active infection of any kind (but excluding fungal infection of nail beds or oral thrush which has resolved before Day 1) within 30 days prior. In addition, any major episode of infection requiring hospitalization or treatment with intravenous anti-infectives in the 30 days prior to Day 1 or oral anti-infectives in the 14 days prior to Day 1
  • Have history of cancer, including solid tumors, hematological malignancies and carcinoma in situ (except basal cell carcinoma of the skin that has been excised and cured)
  • Have history of alcohol or drug abuse in the 52 weeks prior to screening
  • Have had major surgery in the 4 weeks prior to screening excluding diagnostic surgery
  • Have had previous treatment with CAMPATH-1H, a BAFF directed treatment (e.g. anti-BLyS), a B-cell targeted therapy or have received any live vaccine in the 6 weeks prior to Day 1
  • Are pregnant, breastfeeding, or intend to become pregnant during the study
  • Have participated in another research study within the last 30 days

To Learn more
Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Sanita Kandasami, Study Coordinator
Biomedical Research Alliance of New York
The Feinstein Institute for Medical Research
350 Community Drive
Manhasset, NY 11030
Phone: 516-562-2401
Fax: 516-562-2537

View Map

Research Center Information: Biomedical Research Alliance of New York

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 138796

Date Last Changed: July 25, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.